Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaN. Engl. J. Med 2022 Jan 06;386(1)24-34, HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, E Castillo Gutiérrez, P Rutkowski, HJ Gogas, CD Lao, JJ De Menezes, S Dalle, A Arance, JJ Grob, S Srivastava, M Abaskharoun, M Hamilton, S Keidel, KL Simonsen, AM Sobiesk, B Li, FS Hodi, GV Long
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.